Galderma's record H1 performance is partly fueled by a structural shift in patient demand: GLP-1 users seeking to address volume loss and skin laxity triggered by rapid weight reduction. The "Ozempic face" phenomenon—characterized by hollowing, jowling, and loss of skin elasticity—has become a clinical driver for both neuromodulators and volumizing fillers, as well as RF microneedling and biostimulator treatments.